OPRX Insider Trading

Insider Ownership Percentage: 6.10%
Insider Buying (Last 12 Months): $2,542,900.80
Insider Selling (Last 12 Months): $0.00

OptimizeRx Insider Trading History Chart

This chart shows the insider buying and selling history at OptimizeRx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$2.44Mbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

OptimizeRx Share Price & Price History

Current Price: $8.64
Price Change: Price Decrease of -0.1 (-1.14%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for OPRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$8.64Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for OptimizeRx (NASDAQ:OPRX)

76.47% of OptimizeRx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OPRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$32Mbought$10MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
OptimizeRx logo
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
Read More on OptimizeRx

Today's Range

Now: $8.64
Low: $8.34
High: $8.91

50 Day Range

MA: $6.25
Low: $4.14
High: $9.47

52 Week Range

Now: $8.64
Low: $3.78
High: $14.13

Volume

200,589 shs

Average Volume

260,234 shs

Market Capitalization

$159.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Who are the company insiders with the largest holdings of OptimizeRx?

OptimizeRx's top insider shareholders include:
  1. William J Febbo (CEO)
  2. James Paul Lang (Director)
  3. Marion Odence-Ford (General Counsel)
Learn More about top insider investors at OptimizeRx.

Who are the major institutional investors of OptimizeRx?

OptimizeRx's top institutional investors include:
  1. Whetstone Capital Advisors LLC — 7.33%
  2. Royce & Associates LP — 5.81%
  3. Blair William & Co. IL — 3.26%
  4. Kennedy Capital Management LLC — 3.22%
  5. Rice Hall James & Associates LLC — 3.14%
  6. Dimensional Fund Advisors LP — 2.41%
Learn More about top institutional investors of OptimizeRx stock.

Which institutional investors are selling OptimizeRx stock?

Within the last quarter, OPRX stock was sold by these institutional investors:
  1. AWM Investment Company Inc.
  2. G2 Investment Partners Management LLC
  3. Blair William & Co. IL
  4. Rice Hall James & Associates LLC
  5. Sherbrooke Park Advisers LLC
  6. Boothbay Fund Management LLC
  7. Janney Montgomery Scott LLC
  8. Bullseye Asset Management LLC

Which institutional investors are buying OptimizeRx stock?

In the last quarter, OPRX stock was bought by institutional investors including:
  1. Whetstone Capital Advisors LLC
  2. Royce & Associates LP
  3. Tang Capital Management LLC
  4. Kennedy Capital Management LLC
  5. Walleye Capital LLC
  6. Marshall Wace LLP
  7. Manatuck Hill Partners LLC
  8. JPMorgan Chase & Co.
During the last year, these company insiders have bought OptimizeRx stock:
  1. William J Febbo (CEO)
  2. James Paul Lang (Director)
Learn More investors buying OptimizeRx stock.